ADIL Adial Pharmaceuticals Inc

USD 1.19 -0.12 -9.160304999999999
Icon

Adial Pharmaceuticals Inc (ADIL) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.19

-0.12 (-9.16)%

USD 5.55M

3.17M

N/A

N/A

Icon

ADIL

Adial Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 1.19
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 5.55M

N/A

USD 1.19

Adial Pharmaceuticals Inc (ADIL) Stock Forecast

N/A

Based on the Adial Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Adial Pharmaceuticals Inc is not available over the next 12 months. Adial Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adial Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Adial Pharmaceuticals Inc’s stock price was USD 1.19. Adial Pharmaceuticals Inc’s stock price has changed by +11.21% over the past week, +3.48% over the past month and -82.08% over the last year.

No recent analyst target price found for Adial Pharmaceuticals Inc
No recent average analyst rating found for Adial Pharmaceuticals Inc

Company Overview Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trial...Read More

https://www.adialpharma.com

1180 Seminole Trail, Charlottesville, VA, United States, 22901

4

December

USD

USA

Adjusted Closing Price for Adial Pharmaceuticals Inc (ADIL)

Loading...

Unadjusted Closing Price for Adial Pharmaceuticals Inc (ADIL)

Loading...

Share Trading Volume for Adial Pharmaceuticals Inc Shares

Loading...

Compare Performance of Adial Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ADIL

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Adial Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.48 (+0.10%) USD126.85B 31.94 20.00

ETFs Containing ADIL

Symbol Name ADIL's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Adial Pharmaceuticals Inc (ADIL) Stock

Stock Target Advisor's fundamental analysis for Adial Pharmaceuticals Inc's stock is Bearish.

Unfortunately we do not have enough data on ADIL's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ADIL's stock to indicate what its average analyst target is.

ADIL stock's Price/Earning ratio is 0.02. Our analysis grades ADIL stock's Price / Earning ratio at B+. This means that ADIL stock's Price/Earning ratio is above 12% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ADIL may be undervalued for its sector.

The last closing price of ADIL's stock was USD 1.19.

The most recent market capitalization for ADIL is USD 5.55M.

Unfortunately we do not have enough analyst data on ADIL's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Adial Pharmaceuticals Inc's stock.

As per our most recent records Adial Pharmaceuticals Inc has 4 Employees.

Adial Pharmaceuticals Inc's registered address is 1180 Seminole Trail, Charlottesville, VA, United States, 22901. You can get more information about it from Adial Pharmaceuticals Inc's website at https://www.adialpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...